Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dare Bioscience, Inc.DARE · Entity 7799 | Director | June 30, 2026 | July 02, 2026 |
| IDEAYA Biosciences, Inc.IDYA · Entity 4069 | Director | May 31, 2024 | May 31, 2024 |
| IMMUNE DESIGN CORP.IMDZ · Entity 158527 | Director | April 02, 2019 | April 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dare Bioscience, Inc.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 23,696 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 23,696 · Balance 23,696 F1: Represents shares underlying restricted stock units ("RSU") granted to the reporting person in lieu of cash compensation for service on the issuer's board of directors and its committees. Each RSU represents a contingent right to receive one share when vested. The RSUs vests on January 4, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying restricted stock units ("RSU") granted to the reporting person in lieu of cash compensation for service on the issuer's board of directors and its committees. Each RSU represents a contingent right to receive one share when vested. The RSUs vests on January 4, 2027.
IDEAYA Biosciences, Inc.
Report date May 31, 2024 · Filed May 31, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.55 · Expires 2034-05-30 | Direct | 16,200 |
Reported balance
After 2024-05-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-31 · Grant · Acquired 16,200 · Balance 16,200 F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.
IMMUNE DESIGN CORP.
Report date April 02, 2019 · Filed April 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-04-02 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F2: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.05 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-04-02 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F2: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.31 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-04-02 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F2: Not Applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding.
F2: Not Applicable.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARQULE INC
Report date January 16, 2020 · Filed January 16, 2020
Section 16 reporting ended · disclosed 2020-01-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 1
1 source rowRow 1 · 2020-01-16 · Other · Disposed 50,000 · Balance 0 F1: On December 6, 2019, ArQule, Inc. (the "Company") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Merck Sharpe & Dohme Corp. ("MSD") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD ("Merger Sub"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2028-05-08 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-16 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.96 · Expires 2021-04-27 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-16 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.71 · Expires 2021-06-01 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.82 · Expires 2022-05-24 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-01-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.78 · Expires 2023-05-20 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-01-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.42 · Expires 2024-05-13 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-01-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2025-05-11 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-01-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2026-05-24 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-01-16 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2027-05-23 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-01-16 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.21 · Expires 2029-05-13 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-01-16 · Disposition to issuer · Disposed 40,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 6, 2019, ArQule, Inc. (the "Company") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Merck Sharpe & Dohme Corp. ("MSD") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD ("Merger Sub"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price.
F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Deciphera Pharmaceuticals, Inc.
Report date June 11, 2024 · Filed June 12, 2024
Section 16 reporting ended · disclosed 2024-06-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.49 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-11 · Disposition to issuer · Disposed 24,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.27 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-11 · Disposition to issuer · Disposed 9,570 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.98 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-11 · Disposition to issuer · Disposed 18,500 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.27 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-11 · Disposition to issuer · Disposed 3,269 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.91 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-06-11 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 2, 2026 20:21 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantCommon stock | 23,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001401914-26-000036 · wk-form4_1783023690.xml · nonDerivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,696 F1 · shares: Represents shares underlying restricted stock units ("RSU") granted to the reporting person in lieu of cash compensation for service on the issuer's board of directors and its committees. Each RSU represents a contingent right to receive one share when vested. The RSUs vests on January 4, 2027. Read SEC document |
| June 11, 2026 Filed Jun 11, 2026 21:03 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001519612-26-000002 · wk-form4_1781211817.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common stock · 10,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document |
| July 09, 2025 Filed Jul 10, 2025 20:05 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001401914-25-000036 · wk-form4_1752177909.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Underlying: Common stock · 4,500 shares Expires 2035-07-09 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 00:46 UTC | Deciphera Pharmaceuticals, Inc. NA · Entity 90033 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $14.91 | Not disclosed |
DisclosureSEC source: 0000950170-24-072215 · ownership.xml · derivative · entry 5 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 00:46 UTC | Deciphera Pharmaceuticals, Inc. NA · Entity 90033 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,269 | Not disclosed Strike: $21.27 | Not disclosed |
DisclosureSEC source: 0000950170-24-072215 · ownership.xml · derivative · entry 4 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,269 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 00:46 UTC | Deciphera Pharmaceuticals, Inc. NA · Entity 90033 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,500 | Not disclosed Strike: $13.98 | Not disclosed |
DisclosureSEC source: 0000950170-24-072215 · ownership.xml · derivative · entry 3 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,500 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 00:46 UTC | Deciphera Pharmaceuticals, Inc. NA · Entity 90033 | Disposition to issuerStock Option (Right to Buy) · Derivative | 9,570 | Not disclosed Strike: $8.27 | Not disclosed |
DisclosureSEC source: 0000950170-24-072215 · ownership.xml · derivative · entry 2 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,570 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 00:46 UTC | Deciphera Pharmaceuticals, Inc. NA · Entity 90033 | Disposition to issuerStock Option (Right to Buy) · Derivative | 24,000 | Not disclosed Strike: $22.49 | Not disclosed |
DisclosureSEC source: 0000950170-24-072215 · ownership.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:15 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001493152-24-023178 · ownership.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common stock · 40,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document |
| May 31, 2024 Filed May 31, 2024 20:38 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 16,200 | $0.00 Strike: $36.55 | $0.00 |
DisclosureSEC source: 0001610717-24-000278 · form4.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,200 Underlying: Common Stock · 16,200 shares Expires 2034-05-30 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| June 21, 2023 Filed Jun 22, 2023 01:41 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001401914-23-000030 · wk-form4_1687398083.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common stock · 40,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:05 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $14.91 | $0.00 |
DisclosureSEC source: 0001209191-23-039326 · doc4.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-20 F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 21, 2024, subject to continued service through such date. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:47 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 16,200 | $0.00 Strike: $25.40 | $0.00 |
DisclosureSEC source: 0001610717-23-000114 · form4.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,200 Underlying: Common Stock · 16,200 shares Expires 2033-06-06 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:05 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 3,269 | $15.30 Strike: $21.27 | $50,000.01 |
DisclosureSEC source: 0001209191-23-003992 · doc4.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,269 Underlying: Common Stock · 3,269 shares Expires 2033-01-16 F1 · price: These options were issued upon election by the director to receive her cash board retainer fee of $50,000 for the FY 2023 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. The shares will vest in four substantially equal installments on each of March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. F1 · derivative.exercise_date: These options were issued upon election by the director to receive her cash board retainer fee of $50,000 for the FY 2023 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. The shares will vest in four substantially equal installments on each of March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 20:03 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 38,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001401914-22-000056 · wf-form4_165610102252631.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Common stock · 38,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 20:05 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001209191-22-039195 · doc4.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2032-06-22 F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 23, 2023, subject to continued service through such date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 22:27 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $12.29 | $0.00 |
DisclosureSEC source: 0001567619-22-012699 · doc1.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 22:25 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $12.29 | $0.00 |
DisclosureSEC source: 0001567619-22-012698 · doc1.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 22:01 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 9,570 | $5.22 Strike: $8.27 | $49,955.40 |
DisclosureSEC source: 0001209191-22-004084 · doc4.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,570 Underlying: Common Stock · 9,570 shares Expires 2032-01-17 F1 · price: These options were issued upon election by the director to receive her cash board retainer fee of $50,000 for the FY 2022 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. 2,393 shares will vest on March 31, 2022, 2,393 shares will vest on June 30, 2022, 2,393 shares will vest on September 30, 2022 and the remaining 2,391 shares will vest on December 31, 2022. F1 · derivative.exercise_date: These options were issued upon election by the director to receive her cash board retainer fee of $50,000 for the FY 2022 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. 2,393 shares will vest on March 31, 2022, 2,393 shares will vest on June 30, 2022, 2,393 shares will vest on September 30, 2022 and the remaining 2,391 shares will vest on December 31, 2022. Read SEC document |
| June 24, 2021 Filed Jun 24, 2021 20:51 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001401914-21-000098 · wf-form4_162456781006637.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common stock · 30,000 shares Expires 2031-06-24 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 20:00 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $35.86 | $0.00 |
DisclosureSEC source: 0001209191-21-043267 · doc4.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2031-06-22 F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 23, 2022, subject to continued service through such date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 11:10 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $18.91 | $0.00 |
DisclosureSEC source: 0001567619-21-004153 · doc1.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-02-11 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from February 12, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 11:10 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $18.91 | $0.00 |
DisclosureSEC source: 0001567619-21-004152 · doc1.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-02-11 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from February 12, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:00 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 723 | $34.58 Strike: $53.41 | $25,001.34 |
DisclosureSEC source: 0001209191-20-042768 · doc4.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723 Underlying: Common Stock · 723 shares Expires 2030-07-15 F1 · derivative.exercise_date: These options were issued upon election by the director to receive her cash board retainer fee for the second half of 2020 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy and 362 shares will vest on September 30, 2020 and 361 shares will vest on December 31, 2020, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company. Read SEC document |
| June 25, 2020 Filed Jun 27, 2020 00:55 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001401914-20-000093 · wf-form4_159321928214573.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common stock · 22,500 shares Expires 2030-06-25 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:00 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $56.46 | $0.00 |
DisclosureSEC source: 0001209191-20-036233 · doc4.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 10, 2021, subject to continued service through such date. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:57 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $6.21 | Not disclosed |
DisclosureSEC source: 0001104659-20-004729 · tm203607d10_4.xml · derivative · entry 11 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2029-05-13 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:57 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $1.23 | Not disclosed |
DisclosureSEC source: 0001104659-20-004729 · tm203607d10_4.xml · derivative · entry 10 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2027-05-23 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:57 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $1.68 | Not disclosed |
DisclosureSEC source: 0001104659-20-004729 · tm203607d10_4.xml · derivative · entry 9 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-05-24 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:57 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $1.80 | Not disclosed |
DisclosureSEC source: 0001104659-20-004729 · tm203607d10_4.xml · derivative · entry 8 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-05-11 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:57 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $1.42 | Not disclosed |
DisclosureSEC source: 0001104659-20-004729 · tm203607d10_4.xml · derivative · entry 7 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2024-05-13 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:57 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $2.78 | Not disclosed |
DisclosureSEC source: 0001104659-20-004729 · tm203607d10_4.xml · derivative · entry 6 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2023-05-20 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:57 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $5.82 | Not disclosed |
DisclosureSEC source: 0001104659-20-004729 · tm203607d10_4.xml · derivative · entry 5 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2022-05-24 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:57 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $6.71 | Not disclosed |
DisclosureSEC source: 0001104659-20-004729 · tm203607d10_4.xml · derivative · entry 4 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2021-06-01 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:57 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $6.96 | Not disclosed |
DisclosureSEC source: 0001104659-20-004729 · tm203607d10_4.xml · derivative · entry 3 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2021-04-27 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:57 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $2.48 | Not disclosed |
DisclosureSEC source: 0001104659-20-004729 · tm203607d10_4.xml · derivative · entry 2 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2028-05-08 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:57 UTC | ARQULE INC ARQL · Entity 11927 | OtherCommon Stock | 50,000 | $20.00 | $1,000,000.00 |
DisclosureSEC source: 0001104659-20-004729 · tm203607d10_4.xml · nonDerivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 6, 2019, ArQule, Inc. (the "Company") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Merck Sharpe & Dohme Corp. ("MSD") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD ("Merger Sub"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. Read SEC document |
| July 08, 2019 Filed Jul 8, 2019 22:31 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $22.49 | $0.00 |
DisclosureSEC source: 0001209191-19-041483 · doc4.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2029-07-07 F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option vests in 36 equal monthly installments following the vesting commencement date of July 8, 2019, subject to continued service through such dates. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 18:35 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001401914-19-000066 · wf-form4_156053729327372.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common stock · 22,500 shares Expires 2029-06-13 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document |
| May 14, 2019 Filed May 15, 2019 12:22 UTC | ARQULE INC ARQL · Entity 11927 | GrantDirector Stock Options · Derivative | 40,000 | $0.00 Strike: $6.21 | $0.00 |
DisclosureSEC source: 0001019695-19-000019 · primary_doc.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-05-13 F1 · derivative.exercise_date: The options vest 1 year from date of grant. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:12 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 12,500 | Not disclosed Strike: $1.31 | Not disclosed |
DisclosureSEC source: 0001209191-19-023683 · doc4.xml · derivative · entry 3 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F2 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:12 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 12,500 | Not disclosed Strike: $4.05 | Not disclosed |
DisclosureSEC source: 0001209191-19-023683 · doc4.xml · derivative · entry 2 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F2 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:12 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 10,000 | Not disclosed Strike: $5.60 | Not disclosed |
DisclosureSEC source: 0001209191-19-023683 · doc4.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F2 · derivative.expiration_date: Not Applicable. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 20:15 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001209191-19-002657 · doc4.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2029-01-03 F1 · derivative.exercise_date: All shares underlying the option will vest on January 3, 2020. Read SEC document |
| July 10, 2018 Filed Jul 11, 2018 21:44 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001209191-18-042384 · doc4.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-07-10 F1 · derivative.exercise_date: This option vests as to 1/3rd of the shares subject to this option on each of July 10, 2019, 2020 and 2021, subject to the reporting person's continued service to the issuer, and will become exercisable in full upon a change of control of the issuer. Read SEC document |
| May 08, 2018 Filed May 10, 2018 12:16 UTC | ARQULE INC ARQL · Entity 11927 | GrantDirector Stock Options · Derivative | 20,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001019695-18-000002 · primary_doc.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-05-08 F1 · derivative.exercise_date: The options vest 1 year from the date of grant May 8, 2018. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 20:33 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001209191-18-002819 · doc4.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-01-04 F1 · derivative.exercise_date: All shares underlying the option will vest on January 4, 2019. Read SEC document |
| July 19, 2017 Filed Jul 21, 2017 21:21 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantOption to Purchase Common Stock · Derivative | 2,000 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001209191-17-046001 · doc4.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2027-07-19 F1 · derivative.exercise_price: The exercise price reported reflects the 10 for 1 reverse stock split effected by the Corporation on July 20, 2017. F2 · shares: Dr. Kelley was awarded options to purchase shares of the Corporation's common stock in connection with her service as a member of the Board of Directors (the "Director Options") pursuant to the Corporation's 2014 Stock Incentive Plan. F3 · derivative.exercise_date: The Director Options will vest in equal annual installments over a three-year period measured from the date of grant, subject to Dr. Kelley's continued service to the Corporation and will become exercisable in full upon a change of control of the Corporation. Read SEC document |
| July 19, 2017 Filed Dec 8, 2017 21:07 UTC Amendment | Dare Bioscience, Inc. DARE · Entity 7799 | GrantOption to Purchase Common Stock · Derivative | 2,000 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001209191-17-064686 · doc4a.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2027-07-19 F1 · derivative.exercise_price: The exercise price reported reflects the 10 for 1 reverse stock split effected by the Corporation on July 20, 2017. F2 · shares: Dr. Kelley was awarded options to purchase shares of the Corporation's common stock in connection with her service as a member of the Board of Directors (the "Director Options") pursuant to the Corporation's 2014 Stock Incentive Plan. F3 · derivative.exercise_date: The Director Options will vest in full on the earlier of the one year anniversary of the date of grant or immediately prior to the Corporation's 2018 annual meeting of stockholders. F4 · derivative.exercise_date: This form amends a Form 4 previously filed for Dr. Kelley on July 21, 2017, to correct the description of the vesting schedule of the stock options. Read SEC document |
| May 23, 2017 Filed May 24, 2017 10:44 UTC | ARQULE INC ARQL · Entity 11927 | GrantDirector Stock Options · Derivative | 20,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001019695-17-000016 · primary_doc.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-23 F1 · derivative.exercise_date: The options vest one year from the date of grant May 23, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.